| Name | Brilaroxazine |
| Description | Brilaroxazine (RP5063) is a potent multimodal dopamine/5-HT modulator. Brilaroxazine is a partial agonist of dopamine D2, D3, and D4 receptors, 5-HT1A (Ki =1.5 nM) and 5-HT2A (Ki = 2.5 nM), and has antagonist activity 5-HT2B, and 5-HT7 receptors with Kis of 0.19 nM and 2.7 nM, respectively. Brilaroxazine can be used for research about cognitive impairments in neuropsychiatric and neurological diseases. |
| In vivo | Brilaroxazine (10 mg/kg) had efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH, with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 95 mg/mL (210.94 mM), Sonication is recommended.
|
| Keywords | syndrome,ADHD | Serotonin Receptor | RP-5063 | RP 5063 | Pulmonary | Parkinson | PAH | Inhibitor | inhibit | hypertension | DopamineReceptor | Dopamine Receptor | disorder,Tourette | depressive | D4 receptor | D4 Receptor | D3 Receptor | D3 receptor | D2 receptor | D2 Receptor | cardiac | Brilaroxazine | autism | arterial | Alzheimer | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT7 Receptor | 5-HT7 | 5-HT2B Receptor | 5-HT2B | 5-HT2A Receptor | 5-HT2A | 5-HT1A Receptor | 5-HT1A | 5-HT Receptor | 5HT Receptor |
| Inhibitors Related | Alverine citrate | Dapoxetine hydrochloride | Clozapine N-Oxide | Octopamine hydrochloride | D-Menthol | Citicoline | Amitriptyline hydrochloride | Oxolinic acid | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
